Humira maker AbbVie to acquire Botox maker Allergan for $63 billion
Corrections & Clarifications: An earlier version of the story incorrectly stated the company that spun off from Abbott Laboratories. It was AbbVie. Humira maker AbbVie is set to acquire Botox maker Allergan in another move toward consolidation for the pharmaceutical industry. The deal calls for North Chicago, Illinois-based AbbVie to worth about $63 billion for Dublin-based Allergan. Together, the companies have projected 2019 revenue of about $48 billion, including AbbVie's haul from the Humira, a rheumatoid arthritis treatment that Their ...
Click
To Read Full Article